Lipid a from lipopolysaccharide recognition: Structure, dynamics and cooperativity by molecular dynamics simulations

Proteins: Structure, Function and Bioinformatics

Volumn 81, Issue 4, 2013, Pages 658-674

  Garate, Jose Antonio ^a   Oostenbrink, Chris ^a  

^a UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

Author keywords

Free energy; Lipid IVA; MD2; TLR4

Indexed keywords

CELL PROTEIN; LIPID A; LIPOPOLYSACCHARIDE; MYELOID DIFFERENTIATION PROTEIN 2; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

ARTICLE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN STRUCTURE;

ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GLYCOLIPIDS; HOST-PATHOGEN INTERACTIONS; HUMANS; LIPID A; LYMPHOCYTE ANTIGEN 96; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; THERMODYNAMICS; TOLL-LIKE RECEPTOR 4;

EID: 84874809137     PISSN: 08873585     EISSN: 10970134     Source Type: Journal    
DOI: 10.1002/prot.24223     Document Type: Article

References (72)

1. Stewart I, Schluter PJ, Shaw GR. Cyanobacterial lipopolysaccharides and human health-a review. Environ Health 2006; 5: 7-30.
2. Beutler B, Rietschel ET. Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol 2003; 3: 169-176.
3. Christian RH, Raetz CRH, Whitfield C. Lipopolysaccharide endotoxins. Annu Rev Biochem 2002; 71: 635-700.
4. Holst O, Ulmer AJ, Brade H, Flad HD, Rietschel ET. Biochemistry and cell biology of bacterial endotoxins. FEMS Immunol Med Microbiol 1996; 16: 83-104.
5. Bryant CE, Spring DR, Gangloff M, Gay NJ. The molecular basis of the host response to lipopolysaccharide. Nat Rev Microbiol 2009; 8: 8-14.
6. Janway CA, Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symps Quant Biol 1989; 54: 1-13.
7. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 2009; 458: 1191-1195.
8. Kim HM, Park BS, Kim JI, Kim SE, Lee J, Oh SC, Enkhbayar P, Matsushima N, Lee H, Yoo OJ, Lee J. Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist eritoran. Cell 2007; 130: 906-917.
9. Medzhitov R, Preston-Hurlburt P, Janeway CA. A human homologue of the drosophila toll protein signals actIVation of adaptive immunity. Nature 1997; 388: 394-397.
10. Inohara N, Nunez G. ML-a conserved domain involved in innate immunity and lipid metabolism. Trends Biochem Sci 2002; 27: 219-221.
11. Ohto U, Fukase K, Miyake K, Satow Y. Crystal structures of human MD-2 and its complex with antiendotoxic lipid IVa. Science 2007; 316: 1632-1634.
12. Schumann RR, Flaggs GW, Gray PW, Wright SD, Mathison JC, Tobias PS, Ulevitch RJ. Structure and function of lipopolysaccharide binding protein. Science 1990; 249: 1429-1431.
13. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249: 1431-1433.
14. Gangloff M, Gay NJ. MD-2: the toll gatekeeper in endotoxin signalling. Trends Biochem Sci 2004; 29: 294-300.
15. Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, Akira S, Kitamura T, Kosugi A, Kimoto M, Miyake K. Essential role of MD-2 in lps responsiveness and TLR4 distribution. Nature Immunol 2002; 3: 667-672.
16. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M. MD-2, a molecule that confers lipopolysaccharide responsiveness on toll-like receptor 4. J Exp Med 1999; 189: 1777-1782.
17. Walsh C, Gangloff M, Monie T, Smyth T, Wei B, McKinley TJ, Maskell D, Gay N, Bryant C. Elucidation of the MD-2/TLR4 interface required for signaling by lipid IVA. J Immunol 2008; 181: 1245-1254.
18. Kobayashi M, Saitoh S, Tanimura N, Takahashi K, Kawasaki K, Nishijima M, Fujimoto Y, Fukase K, Akashi-Takamura S, Miyake K. Regulatory roles for MD-2 and TLR4 in ligand-induced receptor clustering. J Immunol 2006; 176: 6211-6218.
19. Poltorak A. He X, Smirnova I, Liu MY, Huffel CV, Du X, Birdwell D, Alejos E, Silva M, Galanos C, Freunderberg M, Ricciardi-Castagnoli R, Layton B, Beutler B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in TLR4 gene. Science 1998; 282: 2085-2088.
20. Qureshi ST, Larivière L, Leveque G, Clermont S, Moore KJ, Gros P, Malo D. Endotoxin-tolerant mice have mutations in toll-like receptor 4 (TLR4). J Exp Med 1999; 189: 615-625.
21. Akira S, O. Takeuchi S. Uematsu. Pathogen recognition by innate immunity. Cell 2006; 124: 783-801.
22. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, Frees K, Watt JL, Schwartz DA. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nature Genet 200; 25: 187-191.
23. Rietschel ET, Kirikae T, Schade FU, Mamat U, Schmidt G, Loppnow H, Ulmer AJ, Zahringer U, Seydel U, Di Padova F. Bacterial endotoxin: molecular relationships of structure to activity and function. FASEB J 1994; 8: 217-225.
24. Rietschel ET, Seydel U, Zähringer U, Schade UF, Brade L, Loppnow H, Feist W, Wang MH, Ulmer AJ, Flad HD. Bacterial endotoxin: molecular relationships between structure and activity. Infect Dis Clin N Am 1991; 5: 753-779.
25. Schletter J, Heine H, Ulmer AJ, Rietschel ET. Molecular mechanisms of endotoxin activity. Arch Microbiol 1995; 164: 383-389.
26. Golenbock DT, Hampton RY, Qureshi N, Takayama K, Raetz CR. Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. J Biol Chem 1991; 266: 19490-19498.
27. Teghanemt A, Zhang DS, Levis EN, Weiss JP, Gioannini TL. Molecular basis of reduced potency of underacylated endotoxins. J Immunol 2005; 175: 4669-4676.
28. Zughaier S, Agrawal S, Stephens DS, Pulendran B. Hexa-acylation and KDO2-glycosylation determine the specific immunostimulatory activity of neisseria meningitidis lipid a for human monocyte derived dendritic cells. Vaccine 2006; 24: 1291-1297.
29. Hadina S, Weiss JP, McCray PBJr, Kulhankova K, Thorne PS. MD-2-dependent pulmonary immune responses to inhaled lipooligosaccharides: effect of acylation state. Am J Resp Cell Mol Biol 2008; 38: 647-654.
30. Piazza M, Calabrese V, Damore G, Cighetti R, Gioannini T, Weiss J, Peri F. A synthetic lipid A mimetic modulates human TLR4 activity. ChemMedChem 2012; 7: 213-217.
31. Mullarkey M, Rose JR, Bristol J, Kawata T, Kimura A, Kobayashi S, Przetak M, Chow J, Gusovsky F, Christ WJ, Rossignol DP. Inhibition of endotoxin response by e5564, a novel toll-like receptor 4-directed endotoxin antagonist. J Pharmacol Exp Ther 2003; 304: 1093-1102.
32. Kusumoto S, Fukase K, Fukase Y, Kataoka M, Yoshizaki H, Sato K, Oikawa M, Suda Y. Structural basis for endotoxic and antagonistic activities: investigation with novel synthetic lipid a analogs. J Endotoxin Res 2003; 9: 361-366.
33. Park SH, Kim ND, Jung JK, Lee CK, Han SB, Kim Y. Myeloid differentiation 2 as a therapeutic target of inflammatory disorders. Pharm Ther 2012; 3: 291-298.
34. Mancek-Keber M, Jerala R. Structural similarity between the hydrophobic fluorescent probe and lipid A as a ligand of MD-2. FASEB J 2006; 20: 1836-1842.
35. Resman N, Gradišar H, Vašl J, Mancek-Keber MM, Pristovšek P, Jerala R. Taxanes inhibit human TLR4 signaling by binding to MD-2. FEBS lett 2008; 582: 3929-3934.
36. Manček-Keber M, Gradišar H, Pestaña MI, De Tejada GM, Jerala R. Free thiol group of MD-2 as the target for inhibition of the lipopolysaccharide-induced cell activation. J Biol Chem 2009; 284: 19493-19500.
37. Roh E, Lee HS, Kwak JA, Hong JT, Nam SY, Jung SH, Lee JY, Kim ND, Han SB, Kim Y. MD-2 as the target of nonlipid chalcone in the inhibition of endotoxin LPS-induced TLR4 activity. J Infect Dis 2011; 203: 1012-1020.
38. Gradisar H, Mancek-Keber M, Pristovsek P, Jerala R. MD-2 as the target of curcumin in the inhibition of response to LPS. J leukocyte biol 2007; 82: 968-974.
39. Peluso MR, Miranda CL, Hobbs DJ, Proteau RR, Stevens JF. Xanthohumol and related prenylated flavonoids inhibit inflammatory cytokine production in LPS-activated THP-1 monocytes: structure-activity relationships and in silico binding to myeloid differentiation protein-2 (MD-2). Planta Med 2010; 76: 1536-1543.
40. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007; 316: 1628-1632.
41. Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid a as a safe and effective vaccine adjuvant. Cell Mol Life Sci 2008; 65: 3231-3240.
42. Ulmer AJ, Heine H, Feist W, Kusumoto S, Kusama T, Brade H, Schade U, Rietschel ET, Flad HD. Biological activity of synthetic phosphonooxyethyl analogs of lipid A and lipid A partial structures. Infection and immunity 1992; 60: 3309-3314.
43. Lins RDStraatsma TP. Computer simulation of the rough lipopolysaccharide membrane of pseudomonas aeruginosa. Biophys J 2001; 81: 1037-1046.
44. Soares TAStraatsma TP. Assessment of the convergence of molecular dynamics simulations of lipopolysaccharide membranes. Mol Simul 2008; 34: 295-307.
45. Frecer V, Ho B, Ding JL. Molecular dynamics study on lipid A from escherichia coli: insights into its mechanism of biological action. Biochim Biophys Acta 2000; 1466: 87-104.
46. DeMarco ML, Woods RJ. From agonist to antagonist: Structure and dynamics of innate immune glycoprotein MD-2 upon recognition of variably acylated bacterial endotoxins. Mol Immunol 2011; 49: 124-133.
47. Bernstein FC, Koetzle TF, Williams GJB, Meyer EF, Brice MD, Rodgers JR, Kennard O, Shimanouchi T, Tasumi M. The protein data bank: a computer-based archIVal file for macromolecular structures. J Mol Biol 1977; 112: 535-542.
48. Schlenkrich M, Brickmann J, MacKerell AD, Jr, Karplus M. Empirical potential energy function for phospholipids: criteria for parameter optimization and applications. In: Merz KM, Roux B, editors Biological membranes: a molecular perspective from computation and experiments. Boston: Birkhauser, 1996.
49. MacKerell AD, Bashford D, Bellott, Dunbrack RL, Evanseck JD, Field MJ, Fischer S, Gao J, Guo H, Ha S, Joseph-McCarthy D, Kuchnir L, Kuczera K, Lau FTK, Mattos C, Michnick S, Ngo T, Nguyen DT, Prodhom B, Reiher WE, Roux B, Schlenkrich M, Smith JC, Stote R, Straub J, Watanabe M, Wiorkiewicz-Kuczera J, Yin D, Karplus M. All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 1998; 102: 3586-3616.
50. Feller SE, MacKerell AD. An improved empirical potential energy function for molecular simulation of phospholipids. J Phys Chem B 2000; 104: 7510-7515.
51. Guvench O, Hatcher E, Venable RM, Pastor RW, MacKerell AD, Jr. Charmm additive all-atom force field for glycosidic linkages between hexopyranoses. J Chem Theory Comput 2009; 5: 2353-2370.
52. Guvench O, Greene SN, Kamath G, Brady JW, Venable RM, Pastor RW, MacKerell AD, Jr. Additive empirical force field for hexopyranose monosaccharides. J Comput Chem, 2008; 29: 2543-2564.
53. Klauda JB, Venable RM, Freites JA, OâConnor JW, Tobias DJ, Mondragon-Ramirez C, Vorobyov I, MacKerell AD, Jr, Pastor RW. Update of the charmm all-atom additive force field for lipids: validation on six lipid types. J Phys Chem B 2010; 114: 7830-7843.
54. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys 1983; 79: 926-935.
55. Humphrey W, Dalke A, Schulten K. Vmd: visual molecular dynamics. J Mol Graph 1996; 14: 33-38.
56. Martínez L, Andrade R, Birgin EG, Martínez JM. Packmol: a package for building initial configurations for molecular dynamics simulations. J Comput Chem 2009; 30: 2157-2164.
57. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kalé L, Schulten K. Scalable molecular dynamics with NAMD. J Comput Chem 2005; 26: 1781-1802.
58. Darden T, York D, Pedersen L. Particle mesh Ewald: An N.log(N) method for Ewald sums in large systems. J Chem Phys 1993; 98: 10089-10092.
59. Allen MP, Tildesley DJ. Computer simulation of liquids. USA: Oxford University Press, 1989.
60. Martyna GJ, Tobias DJ, Klein ML. Constant pressure molecular dynamics algorithms. J Chem Phys 1994; 101: 4177-4189.
61. Feller SE, Zhang Y, Pastor RW, Brooks BR. Constant pressure molecular dynamics simulation: The langevin piston method. J Chem Phys 1995; 103: 4613-462.
62. Ryckaert JP, Ciccotti G, Berendsen HJC. Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes. J Comp Phys 1977; 23: 327-341.
63. Aqvist J, Medina C, Samuelsson JE. A new method for predicting binding affinity in computer-aided drug design. Protein Eng 1994; 7: 385-391.
64. Aqvist J, Luzhkov VB, Brandsdal BO. Ligand binding affinities from md simulations. Acc Chem Res 2002; 35: 358-365.
65. Maple JR, Hwang MJ, Stockfish TP, Dinur U, Waldman M, Ewing CS, Hagler AT. derivation of class II force fields. 1. Methodology and quantum force field for the alkyl functional and alkane molecules. J Comput Chem 1994; 15: 162-182.
66. Kabsch W, Sander C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 1983; 22: 2577-2637.
67. Meng J, Lien E, Golenbock DT. MD-2-mediated ionic interactions between lipid A and TLR4 are essential for receptor activation. J Biol Chem 2010; 285: 8695-8702.
68. Clara D Christ, Alan E Mark, andWilfred F van Gunsteren. Basic ingredients of free energy calculations: a review. J Comput Chem 2010; 31: 1569-1582.
69. Pranata J, Jorgensen WL. Monte carlo simulations yield absolute free energies of binding for guaninecytosine and adenineuracil base pairs in chloroform. Tetrahedron 1991; 47: 2491-2501.
70. Viriyakosol S, Tobias PS, Kitchens RL, Kirkland TN. MD-2 binds to bacterial lipopolysaccharide. J Biol Chem 2001; 276: 38044-38051.
71. Akashi S, Saitoh S, Wakabayashi Y, Kikuchi T, Takamura N, Nagai Y, Kusumoto Y, Fukase K, Kusumoto S, Adachi Y, Kosugi A, Miyake K. Lipopolysaccharide interaction with cell surface toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14. J Exp Med 2003; 198: 1035-1042.
72. Gioannini TL, Teghanemt A, Zhang DS, Coussens NP, Dockstader W, Ramaswamy S, Weiss JP. Isolation of an endotoxin-MD-2 complex that produces toll-like receptor 4-dependent cell activation at picomolar concentrations. Proc Natl Acad Sci USA 2004; 101: 4186-4191.